Moderna Puts Its First Seasonal Flu Vaccine In The Clinic

  • Moderna Inc MRNA has initiated a Phase 1/2 study and dosed the first patient with mRNA1010, its quadrivalent vaccine for seasonal flu.
  • The candidate is designed to target lineup lineages that include influenza A H1N1, H3N2, and influenza B Yamagata and Victoria.
  • The 180-subject study will evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010.
  • Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Moderna with a $246 price target after initiating a Phase 1 study of mRNA-1010. 
  • Moderna could "revolutionize" the seasonal flu vaccine market where today's protection rates are only 40%-60%, Tenthoff writes in a research note. 
  • Ultimately Moderna envisions developing a respiratory vaccine that protects against seasonal flu, Covid, and respiratory syncytial virus, says the analyst.
  • Price Action: MRNA shares are down 4.95% at $221.80 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!